Zalicus to Present at the 2012 JMP Securities Healthcare Conference

  Zalicus to Present at the 2012 JMP Securities Healthcare Conference

2012 JMP Securities Healthcare Conference

Business Wire

CAMBRIDGE, Mass. -- July 06, 2012

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and
develops novel treatments for patients suffering from pain and
immuno-inflammatory diseases, today announced that Zalicus management will
present at the 2012 JMP Securities Healthcare Conference at 10:00 a.m. ET on
Thursday, July 12, 2012 at the Peninsula Hotel in New York. Interested parties
may access a live webcast of the presentation by visiting the Zalicus website
at www.zalicus.com. The webcast will be archived on the Zalicus website
following the event.

About Zalicus

Zalicus Inc. (Nasdaq: ZLCS) is a biopharmaceutical company that discovers and
develops novel treatments for patients suffering from pain and
immuno-inflammatory diseases. Zalicus applies its selective ion channel
modulation platform and its combination high throughput screening capabilities
to discover innovative therapeutics for itself and its collaborators in the
areas of pain, inflammation, oncology and infectious disease. To learn more
about Zalicus, please visit www.zalicus.com.

Forward-Looking Statement:

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 concerning Zalicus, its
product candidates, their potential and the plans for their clinical
development, the Zalicus selective ion channel modulation technology, and
related preclinical product candidates, Zalicus’s combination drug discovery
technology, cHTS, and its other business plans. These forward-looking
statements about future expectations, plans, objectives and prospects of
Zalicus may be identified by words like "believe," "expect," "may," "will,"
"should," "seek," “plan” or “could” and similar expressions and involve
significant risks, uncertainties and assumptions, including risks related to
the sale and marketing of Exalgo by Covidien, risks related to the development
and regulatory approval of Zalicus’s product candidates, including risks
relating to formulation and clinical development of Synavive and Prednisporin,
the unproven nature of the Zalicus drug discovery technologies, the ability of
Covidien and Fovea/Sanofi Aventis to perform their obligations under their
agreements with Zalicus, the ability of the Company or its collaboration
partners to initiate and successfully complete clinical trials of its product
candidates, the Company's ability to obtain additional financing or funding
for its research and development and those other risks that can be found in
the "Risk Factors" section of Zalicus's annual report on Form 10-K on file
with the Securities and Exchange Commission and the other reports that Zalicus
periodically files with the Securities and Exchange Commission. Actual results
may differ materially from those Zalicus contemplated by these forward-looking
statements. These forward-looking statements reflect management’s current
views and Zalicus does not undertake to update any of these forward-looking
statements to reflect a change in its views or events or circumstances that
occur after the date of this release except as required by law.

(c) 2012 Zalicus Inc. All rights reserved.

Contact:

Zalicus Inc.
Justin Renz, 617-301-7575
CFO
JRenz@zalicus.com
or
Gina Nugent, 617-460-3579
gnugent@zalicus.com